细胞外囊囊包含由宿主制备的碳,作为载体交换反应以获得中子捕获疗法
Riku Kawasaki1, Ayano Oshige1, Nanami Kono1
1Applied Chemistry Program, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima 739-8527, Japan.
ACS applied materials & interfaces
|August 6, 2024
概括
细胞外囊泡 (EVs) 提供了一种新的,无溶剂的方法,用于加载性药物,如基 (CB) 用于中子捕获疗法 (BNCT). 这种基于EV的药物递送系统在癌症治疗方面在体外和体内表现出卓越的性能.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药物运输 药物运输 药物运输
背景情况:
- 细胞外囊泡 (EVs) 具有较低的免疫性和出色的输送能力,这使得它们成为药物输送的有希望的药物.
- 目前装载疏水分子到电动汽车的方法通常涉及有机溶剂,这可能会破坏电动汽车的结构并造成不良影响.
- 团碳 (CB) 是中子捕获疗法 (BNCT) 的潜在药物,但有效的治疗仍然是一个挑战.
研究的目的:
- 开发一种无溶剂的方法,使用超分子化学将疏水分子装入电动汽车.
- 调查CB装载电动汽车 (CB@EV) 作为BNCT的输送系统的有效性.
- 为了比较CB@EV与现有的输送剂和配方的性能.
主要方法:
- 通过一种基于高分子化学而没有有机溶剂的交换反应来加载疏水分子.
- 在电动汽车中引入疏水性团碳酸 (CB),以创建CB@EVs.
- 在体外和体内评估CB@EVs用于BNCT,包括单颗粒分析,球状透和小鼠瘤积累.
主要成果:
- 交换反应成功地将CB装载到电动汽车中,没有结构破坏或聚合,均地引入货物分子.
- 与L-BPA和脂质体传递的CB相比,CB@EVs在体外显示出更高的BNCT活性,这归因于高效的,独立于内细胞瘤的货物传递.
- CB@EVs在体内显示深入3D球体和瘤组织的选择性积累,增强了BNCT的治疗效益.
结论:
- 无溶剂的超分子化学能够有效地将疏水性药物加载到电动汽车中,从而创建了一个多功能药物递送平台.
- 基于EV的CB用于BNCT的输送,与传统方法相比,具有显著的优势,包括提高疗效和瘤向.
- 这种基于电动汽车的系统对开发先进的抗癌药物输送平台具有很大的前景.
更多相关视频
相关概念视频
Vesicular Tubular Clusters
2.5K
After budding out from the ER membrane, some COPII vesicles lose their coat and fuse with one another to form larger vesicles and interconnected tubules called vesicular tubular clusters or VTCs. These clusters constitute a compartment at the ER-Golgi interface known as ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment). The ERGIC is a mobile membrane-bound cargo transport system that sorts proteins secreted from ER and delivers them to the Golgi.
With the help of motor proteins such...
With the help of motor proteins such...
2.5K
Intralumenal Vesicles and Multivesicular Bodies
3.4K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.4K


